Notice Regarding Recalculated 340B Ceiling Prices for Genentech Products impacted for the time period 3Q 2008 through 2Q 2011

Genentech, Inc. ("Genentech") has recalculated Average Manufacturer Price ("AMP") and Best Price ("BP") values previously submitted to the Centers for Medicare & Medicaid Services ("CMS") for certain products and certain quarters from 1Q 2008 through 4Q 2010. Genentech has also recalculated the 340B ceiling prices for the affected products and associated quarters of 3Q 2008 through 2Q 2011 based on the corrected AMP and BP values.

Genentech has asked the Office of Pharmacy Affairs ("OPA") to post this notice on OPA’s public website to ensure transparency by providing access to information regarding Genentech’s recalculation and refund program to the public and specifically, to any affected 340B Covered Entity.

Genentech will issue refunds to 340B Covered Entities where our data indicates a difference between the original and recalculated 340B ceiling price for direct and indirect purchases of those products listed below.

<table>
<thead>
<tr>
<th>Product Name</th>
<th>NDC</th>
<th>Product Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Activase</td>
<td>50242004413</td>
<td>ACTIVASE – 50 MG</td>
</tr>
<tr>
<td>Activase</td>
<td>50242008527</td>
<td>ACTIVASE – 100 MG</td>
</tr>
<tr>
<td>Aktivase</td>
<td>50242004164</td>
<td>CATHFLO – 2 MG</td>
</tr>
<tr>
<td>Avastin</td>
<td>50242006001</td>
<td>AVASTIN – 4 ML (100 MG)</td>
</tr>
<tr>
<td>Avastin</td>
<td>50242006101</td>
<td>AVASTIN – 16 ML (400 MG)</td>
</tr>
<tr>
<td>Boniva</td>
<td>00004018682</td>
<td>BONIVA – 150 MG TABLET</td>
</tr>
<tr>
<td>Herceptin</td>
<td>50242013468</td>
<td>HERCEPTIN – 440 MG</td>
</tr>
<tr>
<td>Lucentis</td>
<td>50242008001</td>
<td>LUCENTIS – 0.05 ML (0.5 MG)</td>
</tr>
<tr>
<td>Nutropin</td>
<td>50242001821</td>
<td>NUTROPIN - 10 MG</td>
</tr>
<tr>
<td>Nutropin</td>
<td>50242007203</td>
<td>NUTROPIN - 5 MG</td>
</tr>
<tr>
<td>Nutropin</td>
<td>50242002220</td>
<td>NUTROPIN AQ - 2 ML (10 MG)</td>
</tr>
<tr>
<td>Nutropin</td>
<td>50242007301</td>
<td>NUTROPIN AQ - 2 ML (20 MG)</td>
</tr>
<tr>
<td>Nutropin</td>
<td>50242007501</td>
<td>NUTROPIN AQ NUSPIN</td>
</tr>
<tr>
<td>Nutropin</td>
<td>50242004314</td>
<td>NUTROPIN AQ PEN - 2 ML (10 MG)</td>
</tr>
<tr>
<td>Pegasis</td>
<td>00004035239</td>
<td>PEGASYS MONTHLY PACK</td>
</tr>
<tr>
<td>Pegasis</td>
<td>00004035009</td>
<td>PEGASYS – 180 UG/1 ML VIALS 1x2 ML VIALS</td>
</tr>
<tr>
<td>Rituken</td>
<td>50242005121</td>
<td>RITUXAN – 10 ML (100 MG)</td>
</tr>
<tr>
<td>TNKase</td>
<td>50242003861</td>
<td>TNKASE – 50 MG</td>
</tr>
<tr>
<td>Xolair</td>
<td>50242004062</td>
<td>XOLAIR – 150 MG</td>
</tr>
</tbody>
</table>

If any 340B Covered Entity feels they may be eligible for a refund, or has any questions regarding the refund process, Genentech requests those 340B Covered Entities contact Marinell Javier, at (650) 467-3370, or send an email to javier.marinell@gene.com, no later than December 31, 2013.